JNJ-28330835

JNJ-28330835 is a pharmaceutical drug candidate that was developed by Johnson & Johnson. It is a selective androgen receptor modulator (SARM) that was investigated for potential therapeutic applications, but its development was discontinued before it reached the market.

History

JNJ-28330835 was developed by the pharmaceutical company Johnson & Johnson. The company is known for its wide range of healthcare products, including pharmaceutical drugs, medical devices, and consumer packaged goods. JNJ-28330835 was one of the many drug candidates that the company has developed over the years.

Pharmacology

JNJ-28330835 is a selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar properties to anabolic steroids, but with reduced androgenic properties. This property allows SARMs to benefit from the specificity of androgen receptor (AR) action in muscle and bone, while limiting the impact on other tissues, thus helping to reduce potential side effects.

Clinical Development

The clinical development of JNJ-28330835 was discontinued before it reached the market. The reasons for the discontinuation are not publicly disclosed, but it is common for drug candidates to be discontinued during development due to factors such as unfavorable results in preclinical or clinical trials, strategic decisions by the developing company, or potential safety concerns.

See Also

• Selective androgen receptor modulator
• Johnson & Johnson
• Pharmaceutical drug

This article is a stub related to pharmacology. You can help WikiMD by expanding it!